Champions Oncology (CSBR) Receivables (2011 - 2026)

Champions Oncology's Receivables history runs 16 years deep, the most recent figure standing at $18.2 million for Q1 2026.

• In Q1 2026, Receivables fell 15.52% year-over-year to $18.2 million; the TTM figure through Jan 2026 stood at $18.2 million (down 15.52% YoY), while the FY2025 annual figure was $16.6 million, up 7.34% from the prior year.
• Receivables was $18.2 million for Q1 2026 at Champions Oncology, up from $12.6 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $21.6 million in Q1 2025 to a low of $11.7 million in Q4 2023.
• Historically, Receivables has averaged $14.7 million across 5 years, with a median of $13.6 million in 2022.
• Biggest YoY gain for Receivables was 60.81% in 2025; the steepest drop was 26.61% in 2025.
• A 5-year view of Receivables shows it stood at $13.3 million in 2022, then fell by 12.12% to $11.7 million in 2023, then surged by 46.16% to $17.1 million in 2024, then declined by 26.61% to $12.6 million in 2025, then surged by 45.17% to $18.2 million in 2026.
• The last three Receivables figures came in at $18.2 million (Q1 2026), $12.6 million (Q4 2025), and $14.8 million (Q3 2025), per Business Quant data.